Generate Biomedicines opened lower at $12.60, compared with its previous close of $13.49. In the last trading session, the stock traded between $11.50 and $13.33. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 1 year ago in Generate Biomedicines is now worth
$ 99.45
Resulting in a loss of
$ 0.55 (0.55%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 3 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.91 (-6.75%)
Day High
$13.33
Day Low
$11.50
Day Open
$12.60
Prev Close
$13.49
Volume
12,83,699
1W Return
-11.12%
1M Return
-9.19%
3M Return
-11.82%
6M Return
-12.46%
1Y Return
-0.55%
Fundamentals
Market Cap ($ Mn)
-
PE Ratio
-
PB Ratio
4.31
PEG Ratio
-
ROE
-
ROCE
-69.25%
EPS (TTM)
-
Investment Returns
1 Week
-11.12%
1 Month
-9.19%
3 Months
-11.82%
6 Months
-12.46%
9 Months
-0.55%
Financials
Quarterly
All values in $ Mn
10.1
Jun 25
6.3
Jun 26
Updates
12Nov
Generate Biomedicines Q3FY26 Results: Net loss widens 46% to $87.7M
Net loss widened 46% YoY to $87.7 million in Q3FY26. Revenue dropped 56% YoY to $4.2 million, missing estimates. EPS of $(0.68) missed consensus estimate of $(0.59). R&D expenses rose 32% YoY to $82.3 million. Cash position stands at $404.2 million plus $30 million upfront from Zealand.
Today
14Oct
Zealand Pharma signs $1.2 billion AI drug deal with Generate Biomedicines
Generate Biomedicines receives $30 million upfront from Zealand Pharma. Total potential milestone payments reach nearly $1.2 billion. Collaboration targets obesity and metabolic diseases using generative AI. Zealand Pharma handles clinical development and commercialization globally.
29 days ago
26Aug
Generate CTO says Nvidia GPUs essential but won't decide AI drug discovery winners
Generate Biomedicines CTO Gevorg Grigoryan says Nvidia GPUs are essential for AI drug discovery but not a competitive differentiator. Proprietary biological data and experimental measurement scale are cited as key factors for sustainable advantage. The company uses a continuous cycle of molecular generation, testing, and learning to improve AI models over time. Investors are increasingly looking beyond compute infrastructure to companies with proprietary datasets and self-improving AI systems.
2mo ago
6Aug
Generate Biomedicines Q2 Results: EPS beats, sales miss estimates
Generate Biomedicines posted Q2 EPS of $(0.52), beating estimates by 8.77%, while sales of $6.314M missed forecasts by 4.69%. The EPS beat reflects a 73.2% improvement in losses YoY, though revenue fell 37.67% from the prior year's $10.130M.
